Skip to content

Medicare open enrollment has begun! Learn all about it in AARP's Medicare resource center.

 

4-Drug Combo Helps Pancreatic Cancer Patients Live Longer

A study finds a rare sign of progress in attempts to curb the tough-to-treat disease

woman in scarf receiving chemo

Getty Images

A chemotherapy treatment known as folfirinox is showing promising results in patients with pancreatic cancer.

Patients with pancreatic cancer that hadn't spread lived substantially longer on a four-drug combo than on a single standard cancer drug, a rare advance against a tough-to-treat disease, researchers reported Monday.

The results indicate the powerful chemotherapy treatment known as folfirinox will likely become standard of care for the minority of patients whose pancreatic cancer is diagnosed early enough to be removed by surgery, experts not involved in the study said.

After an average three years of follow-up, almost 40 percent of the folfirinox patients were disease-free, compared with about 20 percent who had the standard drug, Gemzar. Overall, almost two-thirds of folfirinox patients were still alive, compared with almost half of Gemzar patients, unexpectedly good results, said Thierry Conroy, the lead author and a cancer specialist at the Cancer Institute of Lorraine in Vandoeuvre-les-Nancy, France.

Results were presented Monday at an American Society of Clinical Oncology conference in Chicago. Richard Schilsky, the group's chief medical officer, called the research an "immediately practice-changing study" and said it's the biggest advance against pancreatic cancer in 25 years.

Folfirinox is already standard treatment for patients whose pancreatic cancer has spread.

The outlook has been bleak for patients with pancreatic cancer, an uncommon disease for which there is no screening. Symptoms including fatigue, weight loss and abdomen pain often don't occur until late, after the disease has spread.

About 330,000 cases are diagnosed each year worldwide, including about 55,000 in the United States. About half are diagnosed after the disease has spread; most die within a year of diagnosis, and only about 6 percent survive for five years.

More News on Cancer

Join the Discussion

0 | Add Yours

Please leave your comment below.

You must be logged in to leave a comment.

GO TO THIS ARTICLE